Inhibition of Galβ1,4GlcNAc α2,6 sialyltransferase expression by antisense‐oligodeoxynucleotides

Glycomic Analysis of Sialic Acid Linkages in Glycans Derived from Blood Serum Glycoproteins

“…Therefore, sialyltransferases have been studied as potential targets for drug development. [37][38][39] Treatment of mouse and human colon cancer cell lines with KI-8110, a specific sialyltransferase inhibitor, has resulted in a significant reduction of cell-surface sialylation and has been shown to dramatically reduce the formation of metastases in the liver and lungs. [40][41][42] Thus, the ability to monitor alterations in the ratios of sialylated glycan isomers in patients diagnosed with breast cancer may also give an indication of the success of a drug treatment program.…”

ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function

“…Strategies designed to halt this process can be aimed at competitively inhibiting the donor with a sugar nucleotide analog, or with an analog of the transition state which binds with many order higher affinity to sialyltransferases than do ground state analogs [ 41 ], or by inhibiting the acceptor with a glucoconjugate analog. Another promising avenue of sialyltransferase inhibition is with antisense-oligodeoxynucleotides, which reduce cell surface sialylation without affecting overall cell viability or growth [ 42 ]. Challenges remain in developing a sialyltransferase inhibitor that is readily bioavailable, but several strategies to circumvent these problems are under investigation.…”

Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases

“…21 Our aim was to study mRNA expression of a panel of glycosyltransferases in colorectal mucosa, adenomas, and carcinomas, and in liver metastases thereof. Expression of each enzyme was compared with that of β-actin co-amplified within the same tube.…”